Movement Alert|Recursion Pharmaceuticals, Inc. Intraday Rise 5.51% in Regular Trading, FDA Alignment Supports REC-4881 Phase 3 Path

Market Focus11-18 22:38

On November 18, Recursion Pharmaceuticals, Inc. rose 5.51% in Regular Trading, trading at $2.8823 per share, with turnover of $5.8009 million.

The move followed the company’s announcement that it aligned with the US Food and Drug Administration on the phase 3 trial design for REC-4881 in familial adenomatous polyposis, providing a clearer regulatory path for a late-stage study.

According to the company update, the study is expected to enroll about 200 patients aged 18 or older who have undergone colectomy or proctocolectomy, and will evaluate REC-4881 at a 4 milligram dose, with the dosing schedule to be determined using data from an ongoing trial. The phase 3 trial remains on track to start in the second half of 2027. Earlier updated TUPELO data had shown deep and durable reductions in polyp burden with a relatively clean safety profile, while the company’s latest quarterly revenue of $18.552 million exceeded the $14.783 million consensus estimate.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment